VSIG10L Activators
VSIG10L activators compromise a diverse array of chemical compounds that indirectly bolster the functional activity of VSIG10L through discrete cellular signaling pathways. Forskolin and IBMX elevate intracellular cAMP levels, activating PKA, which in turn phosphorylates substrates within the signaling networks involving VSIG10L, thereby enhancing its functional role in cellular processes like adhesion. Sphingosine-1-phosphate, through its G-protein coupled receptor interactions, and PMA, as a PKC activator, trigger downstream signaling cascades that intersect with the operational pathways of VSIG10L, ultimately potentiating its activity. Additionally, the PI3K pathway, targeted by LY294002, and the MAPK/ERK pathway, affected by both PD 98059 and U0126, can indirectly enhance VSIG10L's functional activity through the alteration of compensatory signaling routes that VSIG10L may be a part of.
Further contributing to the activation of VSIG10L are compounds that modulate intracellular calcium dynamics and kinase activity. Thapsigargin, by inhibiting the SERCA pump, leads to increased intracellular calcium that activates calcium-dependent signaling pathways, thus enhancing VSIG10L activity. Genistein and Epigallocatechin gallate (EGCG) act as kinase inhibitors, altering the balance of signaling to favor VSIG10L's roles in the cell, while A23187 directly increases calcium levels to support pathways associated with VSIG10L activation. Staurosporine, despite its broad-spectrum kinase inhibition, could selectively tip the balance of cellular signaling in favor of VSIG10L activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin acts by directly stimulating adenylyl cyclase, leading to an increase in cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which then can phosphorylate various targets including factors involved in the signaling pathways that VSIG10L is part of, thus enhancing VSIG10L's activity in cell-cell adhesion. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX, or 3-Isobutyl-1-methylxanthine, is a non-specific inhibitor of phosphodiesterases. By preventing cAMP breakdown, IBMX increases intracellular cAMP levels, similarly leading to the activation of PKA and subsequent phosphorylation of targets in pathways associated with VSIG10L, thereby enhancing its function. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate (S1P) acts on its specific G-protein coupled receptors, which can lead to the activation of multiple signaling cascades, including the PI3K/AKT pathway. This pathway's activation can result in the modulation of cellular processes where VSIG10L is a key component, thus indirectly enhancing VSIG10L activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) is a potent activator of protein kinase C (PKC). Activated PKC phosphorylates target proteins involved in signaling pathways that intersect with VSIG10L functional roles, which enhances VSIG10L's activity in cellular adhesion mechanisms. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. By reducing PI3K activity, there is a compensatory activation of alternative pathways, which could include those where VSIG10L plays a role. This may lead to an indirect enhancement of VSIG10L functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a specific MEK inhibitor, which leads to downregulation of the MAPK/ERK pathway. This downregulation may cause a compensatory upregulation in parallel signaling pathways that could indirectly enhance the activity of VSIG10L in its specific cellular roles. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to an increase in intracellular calcium levels. Elevated calcium can activate calcium-dependent signaling pathways, which in turn can enhance VSIG10L activity, particularly in pathways linked to cellular adhesion and communication. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. By inhibiting certain tyrosine kinases, Genistein may reduce competition for signaling components used by pathways involving VSIG10L, thereby indirectly enhancing its activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a potent antioxidant that also acts as a kinase inhibitor. By modulating kinase activity, EGCG can influence signaling pathways and cellular processes in which VSIG10L is active, enhancing its function. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore, which increases intracellular calcium levels. This elevation can lead to the activation of calcium-dependent proteins and pathways that interact with or regulate VSIG10L, thus enhancing its activity. | ||||||